The Oncotype DX Colon Cancer, Recurrence Score®
Colon cancer is the third most prevalent cancer for both men and women in the United States. It’s also the second most common cause of cancer-related deaths1—yet no two colon cancer patients, or their treatment needs, are the same. Each patient has an individualized level of risk, making the choice of treatment different for everyone. Part of the treatment decision making process involves understanding the likelihood of the colon cancer returning and how a patient’s condition is managed after surgery.
The Oncotype DX Colon Recurrence Score® test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers. The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.
- Prediction of recurrence risk in patients with stage II and III colon cancer
- Disease management and prognosis
Recurrence score0-15: Low risk of recurrence. Prone to adverse effects of chemotherapy and less beneficial effects.
Recurrence score 16-20: Low to medium risk of recurrence. Prone to adverse effects of chemotherapy and less beneficial effects.
Recurrence score <25: Moderate risk of recurrence. Benefits of chemotherapy is greater than the adverse effects.
Recurrence score <25: High risk of recurrence. Benefits of chemotherapy is greater than the adverse effects.
Negative, No pathogenic genes detected
Gene expression by RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction).
FFPE (Formalin-fixed paraffin embedded) tumor tissue
Stability
- Stable at room temperature and refrigerator for a longer period.
Colon biopsy, Hematoxylin and Eosin staining, immunohistochemistry.
- Surg Oncol. 2015 Jun;24(2):61-6. [PMID: 25770397]
- J Clin Oncol 2013;31:4512-9. [PMID: 24220557]
- J Gastrointest Oncol. 2022 Feb;13(1):126-136. [PMID: 35284101]
- Oncologist. 2014 May;19(5):492-7. [PMID: 24710310]
- J Clin Oncol. 2013 May 10;31(14):1775-81. [PMID: 23530100]